Abstract Introduction The Alzheimer's Disease Neuroimaging Initiative (ADNI) has
accumulated 15 years of clinical, neuroimaging, cognitive, biofluid biomarker and genetic …

In Alzheimer's disease, post-mortem studies have shown that the first cortical site where
neurofibrillary tangles appear is the transentorhinal region, a subregion within the medial …

Importance An increased tau positron emission tomography (PET) signal in the medial
temporal lobe (MTL) has been observed in older individuals in the absence of amyloid-β …

This work aimed to investigate potential pathways linking age and imaging measures to
early age-and pathology-related changes in cognition. We used [18F]-Flutemetamol …

Since the invention of 18 F-FDG as a neurochemical tracer in the 1970s, 18 F-FDG PET has
been used extensively for dementia research and clinical applications. FDG, a glucose …

Objective Tau pathology is recognized as a primary contributor to neurodegeneration and
clinical symptoms in Alzheimer's disease (AD). This study aims to localize the early tau …

A major focus of Alzheimer's disease (AD) research has been finding sensitive outcome
measures to disease progression in preclinical AD, as intervention studies begin to target …

Background Crucial to the success of clinical trials targeting early Alzheimer's disease (AD)
is recruiting participants who are more likely to progress over the course of the trials. We …

Alzheimer's disease is defined by the presence of β-amyloid plaques and neurofibrillary tau
tangles potentially preceding clinical symptoms by many years. Previously only detectable …

The medial temporal lobe (MTL) is a nidus for neurodegenerative pathologies and therefore
an important region in which to study polypathology. We investigated associations between …